Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PCDHA9 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
mRNA | PTPRM | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
mRNA | DEDD | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
mRNA | AP3D1 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
mRNA | MMD2 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
mRNA | FNDC3A | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
mRNA | FNDC9 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
mRNA | AL365181.1 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
mRNA | ARHGAP26 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
mRNA | CLASP1 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |